Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication.
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.